NEW YORK (GenomeWeb) – Foundation Medicine said today that is has partnered with Pfizer to develop companion diagnostics for Pfizer's oncology therapies.
The new companion diagnostics will be included in updates to FoundationOne CDx, Foundation Medicine's comprehensive genomic profiling assay for solid tumors that includes multiple companion diagnostics and which was recently approved by the US Food and Drug Administration.
Pfizer will also gain access to Foundation Medicine's data analytics platform, FoundationInsights, to help with biomarker discovery and optimize clinical trial designs.
"We are proud to partner with Pfizer who shares our commitment to precision oncology and biomarker-driven drug development," said Melanie Nallicheri, chief business officer and head of biopharma at Foundation Medicine, in a statement. "The combination of our FDA-approved comprehensive genomic profiling platform and molecular information solutions, coupled with Pfizer’s robust oncology portfolio, enables us to enhance the impact of precision oncology to advance patient care."
FoundationOne CDx is currently FDA approved as a companion diagnostic for patients with certain types of non-small cell lung cancer, melanoma, colorectal cancer, ovarian cancer, or breast cancer to identify those who may benefit from 17 approved targeted therapies.